It is also a leading cause of fatal ICI-related adverse events: among 193 anti-CTLA-4-related deaths, colitis accounted for 70.0% (135 cases) (Wolchok et al., 2010; Hodi et al., 2016). The gene discussed is CTLA4; the disease is colitis.